Clinical Research Directory

Inclusion Criteria: * Age: 18 to 80 years old (inclusive), gender unrestricted. * End-stage renal disease and maintenance hemodialysis for at least 16 weeks. * The average Hb level is 7.0\~10.0 g/dL (the last two evaluations). * And have not received or have discontinued ESA/roxadustat treatment. * Vascular access: internal fistula or long-term hemodialysis catheter. * Weight between 45-100 kg. * Sarcopenia Diagnosis (Reference: AWGS 2019 Consensus): * Decreased muscle strength: Male grip strength \< 28 kg, female grip strength \< 18 kg. * Muscle mass decline: Assessed by bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA), it is characterized by appendicular skeletal muscle mass index (ASMI): \< 7.0 kg/m² for men and \< 5.7 kg/m² for women (BIA standard, the device and formula used should be specified). * Sarcopenia can be diagnosed when both "decreased muscle strength" and "reduced muscle mass" are present. If resources permit, "decreased physical function" (such as a 6-meter walking speed \< 1.0 m/s) can be added as an indicator for severity grading. * Voluntary participation in this study. * Must be able to swallow tablets。 Exclusion Criteria: * Non-renal anemia: Anemia caused by other main reasons (such as thalassemia, megaloblastic anemia due to vitamin B12 or folic acid deficiency, active bleeding, hemolytic anemia, hematological malignancies, etc.). * Contraindications and related risks of Roxadustat: * People who are allergic to roxadustat or any of its excipients. * Uncontrolled hypertension (sitting systolic blood pressure remains \> 160 mmHg or diastolic blood pressure \> 100 mmHg after active antihypertensive treatment). * There have been thrombotic events such as acute myocardial infarction, unstable angina pectoris, stroke, deep vein thrombosis or pulmonary embolism within the past six months. * Those with known active malignant tumors or undergoing anti-tumor treatment (except for basal cell carcinoma, etc.) are excluded. * Diseases affecting muscle metabolism and assessment: * Severe thyroid dysfunction (uncontrolled). * Diagnosed with chronic liver cirrhosis, acute exacerbation of chronic obstructive pulmonary disease (COPD), congestive heart failure (NYHA class IV), and other chronic diseases that seriously affect muscle metabolism. * Due to severe limitations in limb movement caused by rheumatoid arthritis, Parkinson's disease, spinal cord injury, etc., it is impossible to complete muscle strength and functional tests. * Long-term and excessive use of glucocorticoids (equivalent to prednisone \> 7.5 mg/day) or other drugs that may affect muscle metabolism (such as androgens). * Other serious systemic diseases: * Severe liver dysfunction (Child-Pugh grade C or ALT/AST \> 3 times the upper limit of normal). * Active, uncontrolled severe infection. * Life expectancy is less than one year. * Special circumstances related to the research: * A kidney transplant is planned within the next six months. * Has participated in any other interventional clinical trials within the past 3 months. * Poor compliance and special populations: * There are mental or cognitive impairments, making it impossible to understand or cooperate with the research. * Pregnant or lactating women, or women of childbearing age who are unwilling to take effective contraceptive measures during the study period.